Modifiers of liver-related manifestation in the course of NAFLD.
Modifiers of liver-related manifestation in the course of NAFLD.
Curr Pharm Des. 2020 Mar 10;:
Authors: Ekstedt M, Kechagias S, Nasr P, Blomdahl J
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease affecting approximately 25% of the global population. There is a collinearity between the severity of NAFLD and the components of the metabolic syndrome. NAFLD is also independently associated with cardiovascular disease and type 2 diabetes mellitus (T2DM). The progressive potential of non-alcoholic fatty liver disease (NAFLD) is today indisputable, and the histological spectrum of NAFLD ranges from isolated steatosis to non-alcoholic steatohepatitis (NASH), with risk of developing fibrosis and subsequent cirrhosis and hepatocellular carcinoma. There is a substantial inter-patient variation in disease progression, therefore, this review will focus on potential modifiers of fibrosis progression, development of liver cirrhosis, decompensation and liver-related mortality. The potential drivers of disease progression that is discussed are; T2DM and Insulin Resistance, body weight, alcohol consumption, genetics (including HFE and alfa-1-antitrypsin) as well as histological features predictive of disease progression.
PMID: 32156227 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Ekstedt M, Kechagias S, Nasr P, Blomdahl J Tags: Curr Pharm Des Source Type: research
More News: Alcoholism | Cancer & Oncology | Carcinoma | Cardiology | Cardiovascular | Cirrhosis | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fatty Liver Disease (FLD) | Genetics | Heart | Hepatocellular Carcinoma | Insulin | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology